0001509008-14-000001.txt : 20140530 0001509008-14-000001.hdr.sgml : 20140530 20140530141042 ACCESSION NUMBER: 0001509008-14-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20140530 DATE AS OF CHANGE: 20140530 EFFECTIVENESS DATE: 20140530 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Chase Pharmaceuticals Corp CENTRAL INDEX KEY: 0001509008 IRS NUMBER: 208866868 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-218283 FILM NUMBER: 14879241 BUSINESS ADDRESS: STREET 1: 1823 K STREET, NW STREET 2: SUITE 520 CITY: WASHINGTON STATE: DC ZIP: 20006 BUSINESS PHONE: 202-223-7002 MAIL ADDRESS: STREET 1: 1823 K STREET, NW STREET 2: SUITE 520 CITY: WASHINGTON STATE: DC ZIP: 20006 D 1 primary_doc.xml X0707 D LIVE 0001509008 Chase Pharmaceuticals Corp 1825 K STREET NW SUITE 520 WASHINGTON DC DISTRICT OF COLUMBIA 20006 202-223-7002 DELAWARE None None Corporation true John M. Siebert c/o Chase Pharmaceuticals Corporation 1825 K Street NW, Suite 520 Washington DC DISTRICT OF COLUMBIA 20006 Executive Officer Director Thomas N. Chase c/o Chase Pharmaceuticals Corporation 1825 K Street NW, Suite 520 Washington DC DISTRICT OF COLUMBIA 20006 Director Karoly Nikolich c/o Chase Pharmaceuticals Corporation 1825 K Street NW, Suite 520 Washington DC DISTRICT OF COLUMBIA 20006 Director John M. Reher c/o Chase Pharmaceuticals Corporation 1825 K Street NW, Suite 520 Washington DC DISTRICT OF COLUMBIA 20006 Director Greg N. Parekh c/o Chase Pharmaceuticals Corporation 1825 K Street NW, Suite 520 Washington DC DISTRICT OF COLUMBIA 20006 Director Vikram Sudarsan c/o Chase Pharmaceuticals Corporation 1825 K Street NW, Suite 520 Washington DC DISTRICT OF COLUMBIA 20006 Director Raphael Wisniewski c/o Chase Pharmaceuticals Corporation 1825 K Street NW, Suite 520 Washington DC DISTRICT OF COLUMBIA 20006 Director Pharmaceuticals Decline to Disclose 06b false 2014-05-09 false true true true false 1 8586000 6137999 2448001 This filing covers the sale and issuance of Series B-1 Preferred Stock, the Common Stock issuable upon conversion thereof, and the sale and issuance of Series B-1 Preferred Stock Warrants and the Common Stock issuable upon conversion thereof. false 6 0 0 0 true false Chase Pharmaceuticals Corp /s/ John M. Siebert John M. Siebert President and Chief Executive Officer 2014-05-28